The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06111781
• Other study ID #: 2000036163
• Secondary ID: No NIH funding
• Status: Recruiting
• Phase: Phase 2
• Start date: April 15, 2024
• Est. completion date: February 2028

Study information

• Verified date: April 2024
• Source: Yale University
• Contact: Camalene Chrysostoum
• Phone: 860-714-4568
• Email: camalene.chrysostoum[@]yale.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral drug). Treatments will be randomly assigned to study patients. The main questions it aims to answer are the following: 1. Whether the proportion of men who undergo SUGAR have a superior rate of attaining PSA nadir of <= 0.2 compared to SBRT alone, and 2. Whether SUGAR is superior to historical rates of minimal clinically important decline (MCID) in sexual and hormonal function at 6 months for patients undergoing 6 months of androgen deprivation therapy (ADT) Men aged 18+ with cFIR/cgUIR will be enrolled. Specifically, patients must meet one of the following 2 criteria: 1) Gleason score must be Gleason 3+4 with a PSA < 20 ng/mL, or 2) Gleason 6 (3+3) and PSA > 10 ng/mL and < 20 ng mL.

Description:

Unfavorable Intermediate Risk (UIR) Prostate Cancer is prostate cancer that is localized and curable but may require more treatment than external beam radiotherapy (EBRT) alone. In contrast, favorable intermediate risk (FIR) prostate cancer can be treated by EBRT alone. There is evidence that some prostate cancer that is classified through clinical factors as FIR can act more aggressively if also associated with a high risk gene expression score. This type of prostate cancer (traditionally favorable intermediate risk, but with a gene signature that predicts for aggressive disease) presents a treatment dilemma. Recent evidence suggests that androgen deprivation therapy (ADT) is generally beneficial for intermediate risk prostate cancer and so it is possible that these patients (with favorable intermediate risk based on non-genetic factors but with high genetic risk) may also benefit. However, ADT causes very bothersome side effects including hot flashes, fatigue, sexual disfunction, and in some cases, heart problems. In order to balance the benefit and harms of ADT in combination with radiation, we could reduce the length of ADT and make it precisely overlap with radiation treatment. The oral ADT medication Relugolix (Orgovyx) is ideal for this purpose. In addition to shortening ADT, it is important to measure any potential benefit when ADT is added to stereotactic body radiotherapy (SBRT). SBRT is a shorter and more intense version of standard fractionation EBRT. Therefore, a multicenter randomized phase III study comparing prostate cancer control and quality of life with SBRT + Ultrashort GNRH Antagonist Relugolix (SUGAR) vs. SBRT alone for a category of clinicogenomic unfavorable intermediate risk patients with favorable clinical features and high risk genetic features.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 2028
• Est. primary completion date: February 2028
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate

4. Born assigned to Male gender, age 18 and above. Female identifying transgender or gender fluid are allowed on study provided they have not undergone testosterone suppressing therapy and were born with a prostate.

5. Has a serum testosterone at the Screening visit of >150 ng/dL

6. Has a serum PSA concentration at the Screening visit of > 0.2 ng/mL

7. Able to swallow pills and take medication orally (no documented inability to eat solids and swallow pills) and be willing to adhere to the tice daily regimen of medication (if assigned to the experimental arm).

8. For patients of reproductive potential: use of condoms or other methods (including abstinence) to ensure effective contraception with partner during radiotherapy and through 4 months after the last dose of the study drug or radiotherapy

9. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration

10. Clinical favorable intermediate risk prostate cancer: Gleason score must be Gleason 3+4 with a PSA < 20 ng/mL, or Gleason 6 (3+3) and PSA > 10 ng/mL and < 20 ng mL.

11. Decipher GC score of 0.6 or higher or higher indicating high genomic risk for most recent biopsy

12. Documented prostate volume (by MRI or ultrasound) <= 80 cc

Exclusion Criteria:

1. Current use of medications that cause QT prolongation

2. Known allergic reactions to relugolix

3. Treatment with another investigational drug or other intervention for prostate cancer within 30 days of enrollment

4. Ulcerative colitis or other inflammatory bowel disease history

5. Connective tissue disease such as lupus, scleroderma, or dermatomyositis

6. GNRH antagonist therapy or SBRT to the prostate are medically contraindicated or not tolerated

7. History of long QT syndrome documented in the medical record

8. The following ECG abnormalities are excluded:

1. Q-wave infarction unless identified 6 or more months before the Screening Visit

2. QT interval corrected for heart rate (QTc) > 470 msec. If the QTc is prolonged in a patient with a pacemaker, the patient may be enrolled in the study upon discussion with the study PI

3. Congenital long QT syndromeQ

9. History of surgical castration

10. Prior treatment for prostate cancer with surgery or prostate directed radiotherapy

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Relugolix 120 MG [Orgovyx]
ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.

Radiation:
• SBRT standard of care radiotherapy treatment
SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.

Locations

Country	Name	City	State
United States	Yale Cancer Center	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants that attain PSA nadir	The proportion of men who undergo SUGAR that attain PSA nadir of <= 0.2ng/mL compared to SBRT alone.	up to 2 years post treatment
Secondary	Change in Quality of life assessment using the EPIC-26 survey	The EPIC-26 is a validated instrument that measures health-related quality of life over 5 domains: Urinary incontinence, Urinary irritative/obstructive, Bowel, Sexual, Hormonal. Range of scores are 0-100. Higher scores indicate higher quality of life.	up to 2 years post treatment